Ryan’s Quest, Michael’s Cause, and Pietro’s Fight have committed the $400,000 in seed capital toward developing DMD-813, which has shown promise in preclinical studies
Ryan’s Quest, Michael’s Cause, and Pietro’s Fight have committed the $400,000 in seed capital toward developing DMD-813, which has shown promise in preclinical studies